<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04404049</url>
  </required_header>
  <id_info>
    <org_study_id>UBP-A218-HIV</org_study_id>
    <nct_id>NCT04404049</nct_id>
  </id_info>
  <brief_title>The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients</brief_title>
  <acronym>HIV-1</acronym>
  <official_title>The HIV Functional Cure Potential of UB-421: A Phase II, Randomized, Open-label, Controlled, 48 Week, Proof of Concept Study, to Evaluate the Safety of UB-421 in Combination With Standard Antiretroviral Therapy (ART) and the Efficacy of HIV Reservoir Reduction as Compared With ART Alone in ART Stabilized HIV-1 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UBP Greater China (Shanghai) Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UBP Greater China (Shanghai) Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, randomized, open-label, multi-center, active-controlled study to assess
      the safety, tolerability, and efficacy of UB-421 administered as an add-on to the standard
      ART in ART-treated HIV-1 subjects with stably suppressed HIV-1 plasma VL. The study will be
      conducted at multiple study centers, designated AIDS hospitals in China.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment related TEAEs</measure>
    <time_frame>48Weeks</time_frame>
    <description>the incidence of Grade 3 drug-related treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change of immune profiles</measure>
    <time_frame>16Weeks</time_frame>
    <description>Change in Treg percentage in the peripheral blood</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Standard ART</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will receive standard ART for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-421(25mg/kg) Q2W add-on treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-421(25mg/kg) Q4W add-on treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-421(25 mg/kg) Q2W</intervention_name>
    <description>Monoclonal antibody by IV infusion plus standard ART</description>
    <arm_group_label>UB-421(25mg/kg) Q2W add-on treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-421(25 mg/kg) Q4W</intervention_name>
    <description>Monoclonal antibody by IV infusion plus standard ART</description>
    <arm_group_label>UB-421(25mg/kg) Q4W add-on treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 sero-positive

          2. Male with body weight ≥ 50 kg or female with body weight ≥ 45 kg.

          3. HIV-1 plasma RNA level below 50 RNA copies/mL.

        Exclusion Criteria:

          1. Subjects with active systemic infections, except for HIV-1, that the Investigator
             feels the infections may confound evaluation and treatment for HIV-1.

          2. Current active hepatitis B carriers, ie, hepatitis B surface antigen positive.

          3. Current active hepatitis C carriers, ie, hepatitis C virus (HCV) antibody positive.

          4. History of anaphylaxis to other mAbs.

          5. Any vaccination within 8 weeks prior to the first dose of assigned drug.

          6. Use of immunomodulators, HIV vaccine, or systemic chemotherapy within 180 days prior
             to the first dose of assigned drug.

          7. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

